Given the high protection rates of S4ΔaroD and S4ΔguaBA in Rbs (50 and 73% respectively), we envision that NHP studies with these strains would both advance tularemia vaccines and further test the notion that Rb-derived COPs have clinical utility. This evidence concerns the gene ESCO2 and tularemia.